FDA panel endorses Lamictal XR as monotherapy for epilepsy - Related Stories - AAP SmartBrief
Links shared publicly online about this topic.
- 438total visits
FDA panel endorses Lamictal XR as monotherapy for epilepsy - Related Stories - AAP SmartBrief
An FDA advisory panel supported GlaxoSmithKline's request to convert Lamictal XR into stand-alone therapy for partial-onset epilepsy in patients age 13 and older. GSK said clinical data provide substantial evidence of monotherapy effectiveness.
View full resource at smartbrief.com
Tags: Seizure, Seizure Medication, Epilepsy, FDA, American Academy of Pediatrics, Lamictal, Epilepsy Medication
Most Recently Shared on March 15, 2011 at 1:07 pm By:
FDA panel endorses Lamictal XR as monotherapy for epilepsy http://sbne.ws/r/6Zdd
Advertisement
